title: Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer.
abstract: OBJECTIVE
  HuR, human family embryonic-lethal abnormal vision-like protein, can bind to mRNA and stabilizes the nucleic acid in the cytoplasm, resulting in more efficient translation. HuR is predominantly present in the nucleus and shuttles between the nucleus and cytoplasm. HuR stabilizes cyclooxygenase-2 (Cox-2) mRNA in several cancers, including breast, stomach, lung and brain cancer.
  
  
  METHODS
  We investigated the expression and cellular location of HuR, as well as evaluated Cox-2 expression in 79 colorectal cancer patients with the use of immunohistochemical methods. The biological implications of HuR localization and Cox-2 expression in colorectal carcinoma were evaluated.
  
  
  RESULTS
  Nuclear HuR expression was observed in 59 (74.7%) tumors and cytoplasmic HuR expression was seen in 25 (31.6%) tumors. Cox-2 immunoreactivity was noted in 42 (53%) tumors. The expression of cytoplasmic HuR was significantly associated with Cox-2 expression (p=0.004). Cytoplasmic expression of HuR showed a correlation with lymphatic invasion (p=0.025) and the presence of a lymph node metastasis (p=0.027). The presence of nuclear HuR showed no correlation with Cox-2 expression or any other of the clinicopathological parameters that were examined.
  
  
  CONCLUSIONS
  These results suggest that cytoplasmic translocation of HuR is associated with Cox-2 expression for some colorectal carcinomas.
authors.affiliation: Department of Pathology, East-West Neo Medical Center, KyungHee University College of Medicine, Seoul, Korea.
authors.forename: Sung-Jig
authors.initials: SJ
authors.lastname: Lim
authors.forename: Suk-Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Sun Hyung
authors.initials: SH
authors.lastname: Joo
authors.forename: Jeong Yoon
authors.initials: JY
authors.lastname: Song
authors.forename: Sung Il
authors.initials: SI
authors.lastname: Choi
references.citation: Cancer Res. 2004 Jan 1;64(1):189-95
references.pmid: 14729623
references.citation: Int J Gynecol Pathol. 2007 Jul;26(3):229-34
references.pmid: 17581403
references.citation: J Biol Chem. 2003 Sep 26;278(39):37637-47
references.pmid: 12826679
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10611-6
references.pmid: 12149460
references.citation: Mol Cell Biol. 2002 May;22(10):3425-36
references.pmid: 11971974
references.citation: Hum Pathol. 2004 Apr;35(4):488-95
references.pmid: 15116331
references.citation: Mol Cell Biol. 2003 Oct;23(20):7177-88
references.pmid: 14517288
references.citation: EMBO J. 1998 Jun 15;17(12):3448-60
references.pmid: 9628880
references.citation: J Biol Chem. 2000 Apr 21;275(16):11750-7
references.pmid: 10766797
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40
references.pmid: 9096394
references.citation: Oncology. 2004;66(4):275-80
references.pmid: 15218294
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7362-8
references.pmid: 16243808
references.citation: EMBO J. 2000 May 15;19(10):2340-50
references.pmid: 10811625
references.citation: Biochem J. 1996 Aug 15;318 ( Pt 1):325-31
references.pmid: 8761489
references.citation: J Clin Invest. 2001 Dec;108(11):1657-65
references.pmid: 11733561
references.citation: Chem Biol. 2002 Nov;9(11):1161-2
references.pmid: 12445764
references.citation: Science. 2001 Nov 30;294(5548):1895-901
references.pmid: 11729309
references.citation: J Cell Sci. 1998 Nov;111 ( Pt 21):3145-56
references.pmid: 9763509
references.citation: J Biol Chem. 1996 Apr 5;271(14):8144-51
references.pmid: 8626503
references.citation: Trends Biochem Sci. 1995 Nov;20(11):465-70
references.pmid: 8578590
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Mol Cell Biol. 2000 Feb;20(3):760-9
references.pmid: 10629032
references.citation: Eur J Biochem. 2003 Jan;270(2):350-65
references.pmid: 12605686